Skip to content
Forest Global Training Partners
Home Services AI Governance AI Navigators Contact Us
AI Navigators AI Use CasesAI RisksAI Hallucinations Topics Entities Sources
  1. Home
  2. AI Hallucinations
  3. Preventing Bias in AI: Q&A with Michael Armstrong…

AI Hallucinations June 21, 2024 · Pharmaceutical Executive

Preventing Bias in AI: Q&A with Michael Armstrong - Pharmaceutical Executive

PE: How do combat the issue of AI hallucination s? Armstrong: That's a challenge across the board. First off, we need to ask what a hallucination is …

Read the original at Pharmaceutical Executive ↗

Topics
Hallucinations & FabricationBias & FairnessHealthcare
Tracked via
Google Alert “AI hallucination”

Related articles

  • Potential Risksof Relying on Open-AccessAIModels - Pharmaceutical Executive AI Risks · Feb 10, 2025
  • Driving Field Excellence withAI-Enhanced Rep Support - Pharmaceutical Executive AI Hallucinations · Dec 18, 2024
  • The Leap Forward: Practical Gains for PharmaAIUse - Pharmaceutical Executive AI Risks · Nov 14, 2024
  • How AI is Changing the Drug Development Journey - Pharmaceutical Executive AI Risks · Feb 22, 2024
  • Avicenna.AI Receives EU Certification for AI Imaging Products - Pharmaceutical Executive AI Use Cases · Jul 08, 2024
  • Can government and industry solve racial bias in AI? - Healthcare IT News AI Risks · Dec 21, 2023

AI Navigators is a curated research index from Forest Global Training Partners. Articles belong to their publishers; we link to and summarize them.

Contact